CVS results top expectations, lifted by strong health services revenue

CVS results top expectations, lifted by strong health services revenue


A woman walks past a CVS Pharmacy in Washington, D.C., on Nov. 2, 2022.

Brendan Smialowski | AFP | Getty Images

CVS on Wednesday reported third-quarter adjusted earnings and revenue that topped Wall Street’s expectations, lifted in part by strong revenue from the company’s health services business. 

CVS booked sales of $89.76 billion for the quarter, up nearly 11% from the same period a year ago.

The company reported net income of $2.27 billion, or $1.75 per share, for the third quarter. That compares with a net loss of $3.40 billion, or $2.59 per share, for the same period a year ago. Excluding certain items, such as amortization of intangible assets and capital losses, adjusted earnings per share were $2.21 for the quarter.

Here’s what CVS reported for the third quarter compared to what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv:

  • Earnings per share: $2.21 adjusted vs. $2.13 expected
  • Revenue: $89.76 billion vs. $88.25 billion expected

CVS lowered its full-year unadjusted earnings forecast to a range of $6.37 to $6.61, down from a prior range of $6.53 to $6.75. However, it maintained its forecast on an adjusted basis, guiding to full-year adjusted earnings of $8.50 to $8.70 per share. 

The results come on the last day of a nationwide walkout by pharmacy staff from CVS, Walgreens and Rite Aid to protest what they call harsh working conditions that put both employees and patients at risk. CVS told CNBC last week that the company is engaging with staff to directly address any concerns that they might have. 

They also come one quarter after CVS launched a sweeping cost-cutting program as part of its push to transform from a major drugstore chain to a large health-care company. The company deepened that push earlier this year with its nearly $8 billion acquisition of health-care provider Signify Health and $10.6 billion deal to buy Oak Street Health, which operates primary care clinics for seniors.

Shares of CVS were down nearly 26% for the year through Monday’s close, putting the company’s market value at around $88 billion. 

Growth across business segments 

The company’s health services segment generated $46.89 billion in revenue for the quarter, a nearly 8% increase compared with the same quarter in 2022. The division includes CVS Caremark, which negotiates drug discounts with manufacturers on behalf of insurance plans, as well as health-care services delivered in medical clinics, through telehealth and at home.

Analysts had expected the division to bring in $45.19 billion in sales, according to estimates compiled by StreetAccount.

CVS said the increase was driven in part by growth in specialty pharmacy services, which help patients who are suffering from complex disorders and require specialized therapies. The company’s recent acquisitions of Oak Street Health and Signify Health also boosted the segment results, according to CVS.

The division processed 579.6 million pharmacy claims during the quarter, a slight decrease from the year-ago period due to a drop in Covid vaccinations and a Medicaid customer contract change. 

The company’s pharmacy and consumer wellness division booked $28.87 billion in sales for the quarter, up 6% from the year-ago period. That segment dispenses prescriptions in CVS’s retail pharmacies and provides other pharmacy services, such as diagnostic testing and vaccination. 

Analysts had expected the division to bring in $28.81 billion in sales, according to estimates compiled by StreetAccount.

Same-store sales grew 8.8% during the three-month period compared with the same time a year earlier, but not equally across the store. Same-store sales jumped 11.9% in the pharmacy division, but were down by 2.2% in the front of the store, in part as customers cut back on buying over-the-counter Covid tests.

CVS said a slight increase in prescription volume contributed to the segment’s revenue growth. The division filled 407.1 million prescriptions during the quarter, fractionally up from the same period a year ago. But same-store prescription volume jumped nearly 3.5%, excluding Covid vaccines.

The company counts 9,000 brick-and-mortar drugstores across the U.S.

CVS’s health insurance segment generated $26.30 billion during the quarter, a nearly 17% increase from the second quarter of 2022. That division includes plans by CVS-owned health insurer Aetna for the Affordable Care Act, Medicare Advantage, Medicaid, and dental and vision.

The insurance segment’s medical benefit ratio— a measure of total medical expenses paid relative to premiums collected — increased to 85.7% from 83.4% a year earlier. A lower ratio typically indicates that the company collected more in premiums than it paid out in benefits, resulting in higher profitability.

Analysts had expected that ratio to be 84.7%, according to StreetAccount estimates.

CVS will hold an earnings call with investors at 8 a.m. ET.



Source

Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says
Health

Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says

The CEO of Novartis said Wednesday that the Swiss pharmaceutical giant does not plan to enter into the “frenzy” of weight loss drugs, preferring instead to focus on areas where it can build a “unique position.” Speaking to CNBC, Vas Narasimhan said that the company was researching treatments that deal with the secondary effects of […]

Read More
23andMe CEO Anne Wojcicki ‘surprised and disappointed’ by board resignations: Read the memo
Health

23andMe CEO Anne Wojcicki ‘surprised and disappointed’ by board resignations: Read the memo

Anne Wojcicki, co-founder and chief executive officer of 23andme Inc., during the South by Southwest (SXSW) festival in Austin, Texas, US, on Friday, March 10, 2023.  Jordan Vonderhaar | Bloomberg | Getty Images All seven independent directors of 23andMe resigned from the company’s board Tuesday, a move that CEO Anne Wojcicki said left her “surprised […]

Read More
Healthy Returns: How competitive can Roche be in the weight loss drug market?
Health

Healthy Returns: How competitive can Roche be in the weight loss drug market?

Headquarters of Roche, multinational pharmaceutical industry on December 27, 2021 in Madrid, Spain.  Cristina Arias | Cover | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good afternoon! Roche is one of several drugmakers […]

Read More